Akebia Therapeutics, Inc. (AKBA) Stock Forecast
AKBA analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.50 / 5 from 6 analysts
- Price target
- $3.92 average of analyst targets
- Upside to target
- +484.6% from the latest close
- Next earnings
- November 9, 2026 EPS estimate $-0.03
- 52-week range
- $0.67 – $3.17
AKBA analyst ratings
6 analystsNumber of analysts at each rating.
AKBA price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
AKBA earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.03 | −$0.04 | −$0.02 | $0.00 | 0.0% | 2 |
| Current fiscal year (2026) | −$0.16 | −$0.16 | −$0.16 | −$0.02 | −700.0% | 1 |
| Next fiscal year (2027) | −$0.36 | −$0.39 | −$0.33 | −$0.16 | −125.0% | 2 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
AKBA revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $46.9M | $43.0M | $51.4M | −20.1% | 6 |
| Current fiscal year (2026) | $197.8M | $186.6M | $212.8M | −16.2% | 6 |
| Next fiscal year (2027) | $132.5M | $94.8M | $162.6M | −33.0% | 6 |
AKBA EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
AKBA revenue: reported and forecast
AKBA EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.03 | −$0.03 | −$0.04 | −$0.04 | −$0.03 | 0.0% | 1 up · 0 down |
| Current fiscal year (2026) | −$0.10 | −$0.10 | −$0.10 | −$0.13 | −$0.16 | +52.4% | 0 up · 1 down |
| Next fiscal year (2027) | −$0.19 | −$0.19 | −$0.20 | −$0.33 | −$0.36 | +89.5% | 0 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
AKBA earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; AKBA beat in 8 of 12.
What analysts expect from AKBA
6 analysts cover Akebia Therapeutics; their consensus rating is strong buy (4.50 on a 1–5 scale, where 5 is a strong buy). The average price target is $3.92, 484.6% above the latest close of $0.67. Analysts expect earnings of −$0.16 per share for 2026, −700.0% from a year earlier. For 2027 the average estimate is −$0.36 per share on revenue of $132.5 million. Akebia Therapeutics beat the EPS estimate in 8 of the last 12 quarters.
Related: AKBA income statement, AKBA key metrics, AKBA chart. See the AKBA stock overview for the latest quote and news.
AKBA forecast FAQ
What is Akebia Therapeutics's price target?
The average analyst price target for Akebia Therapeutics is $3.92, 484.6% above the latest close of $0.67.
Is Akebia Therapeutics a buy, hold or sell?
Of 6 analysts covering Akebia Therapeutics, 4 rate it a strong buy, 1 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Akebia Therapeutics's EPS forecast?
Analysts forecast −$0.16 per share for 2026 (range −$0.16 to −$0.16); for 2027 the estimate is −$0.36.
What is Akebia Therapeutics's revenue forecast?
The average revenue estimate for 2026 is $197.8 million, growth of −16.2%; for 2027 it is $132.5 million.
When does Akebia Therapeutics report earnings?
Akebia Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 9, 2026 after the market closes; the EPS estimate is $-0.03.
Does Akebia Therapeutics usually beat earnings estimates?
Akebia Therapeutics reported EPS at or above the analyst estimate in 8 of the last 12 quarters.